| I-54 Félix Jaminion Use of a drug-drug interaction study with itraconazole to quantify the effects of an NME on QT interval duration Wednesday 10:20-11:40 |
| I-61 Anhye Kim Population Pharmacokinetic/Pharmacoynamic Models to evaluate the positive and delayed effect of escitalopram on QT prolongation Wednesday 10:20-11:40 |
| I-65 Gilbert Koch Facilitate treatment adjustment after accidental overdosing: pharmacometric modelling to support clinical practice Wednesday 10:20-11:40 |
| II-12 Hyun-moon Back Development of QT prolongation model in guinea pig with hERG assay-in vivo PK- in-vivo QT effect to guide decision making in early drug discovery Wednesday 15:10-16:30 |
| II-20 Brendan Bender An integrated pharmacokinetic-pharmacodynamic modeling analysis of T-DM1–induced thrombocytopenia and hepatotoxicity in patients with HER2-positive metastatic breast cancer Wednesday 15:10-16:30 |
| II-73 Anne-Gaelle Dosne Robust QT prolongation assessment using model-averaging Wednesday 15:10-16:30 |
| III-07 Dominik Lott Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod Thursday 10:05-11:30 |
| III-48 Alejandro Pérez-Pitarch Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes Mellitus: Modelling Rate and Severity of Hypoglycemic Events Thursday 10:05-11:30 |
| IV-35 Mirjam Trame Development of a Mechanism Based Platform to Predict Cardiac Contractility and Hemodynamics in Conscious Dogs Thursday 14:40-16:00 |
| IV-56 Sebastian Weber Modeling Recurrent Safety Events in Drug Combinations using a Time-Varying Poisson Process Thursday 14:40-16:00 |
| IV-78 Jochen Zisowsky A Method to Perform PK-QT Analyses When Several Active Compounds or Metabolites Are Present Thursday 14:40-16:00 |
